| Not Yet Recruiting | Micro Assays for HemATology Malignancies Antibody Treatment NCT07018310 | Assistance Publique Hopitaux De Marseille | N/A |
| Recruiting | Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies NCT06758713 | The Third Affiliated Hospital of Southern Medical University | Phase 1 |
| Active Not Recruiting | Investigation of the Effects of Prehabilitation Education Delivered Through a Mobile Compatible Website on Qua NCT07066592 | Saglik Bilimleri Universitesi | N/A |
| Recruiting | Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hema NCT06584006 | The First Affiliated Hospital of Xiamen University | Phase 2 |
| Recruiting | A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product NCT05768269 | Century Therapeutics, Inc. | — |
| Recruiting | Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphod NCT05110742 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Unknown | PROPHYLAXIS OF GVH IN ELDERLY PATIENTS RECEIVING HAPLOIDENTICAL ALLOGENIC HEMATOPOIETIC STEM CELL TRASNPLANTAT NCT06066255 | Institut Paoli-Calmettes | Phase 2 |
| Unknown | Is Ibrutinib-related Atrial Fibrillation Dose Dependent NCT06224452 | University Hospital, Caen | — |
| Unknown | Physical Therapy in Patients Undergoing Allo-HSCT With cGVHD NCT06279585 | University of Seville | N/A |
| Recruiting | Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia NCT05537896 | West Virginia University | Phase 2 |
| Recruiting | An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of NCT06225856 | Shanghai Yuyao Biotech Co., Ltd. | Phase 1 |
| Recruiting | A Pilot Prospective Clinical Trial Using Remote Monitoring for Cancer Patients Undergoing Outpatient Chemother NCT06106360 | Inova Health Care Services | — |
| Completed | A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007) NCT06586671 | Merck Sharp & Dohme LLC | Phase 1 |
| Recruiting | First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors NCT05828459 | Onward Therapeutics | Phase 1 |
| Completed | The Effect of Music Therapy on Comfort, Pain and Anxiety NCT05895357 | Izmir Bakircay University | N/A |
| Terminated | SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma. NCT05293912 | Hangzhou Sumgen Biotech Co., Ltd. | Phase 1 |
| Unknown | A Study of Shengxuening Tablet in the Treatment of Chemotherapy-related Anemia in Hematologic Tumors NCT05784870 | Zhongnan Hospital | Phase 3 |
| Unknown | The Optimization of Haploidentical Hematopoietic Stem Cell Transplantation NCT05629260 | Peking University People's Hospital | — |
| Unknown | Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malig NCT05510089 | The Affiliated People's Hospital of Ningbo University | N/A |
| Completed | DxFLEX 10C Clinical Study NCT05467449 | Beckman Coulter, Inc. | — |
| Unknown | Individual Dietary Counseling Based on Taste-tests in Patients With Hematological Cancer in Cytostatic Therapy NCT05364359 | University of Copenhagen | N/A |
| Recruiting | CXCR4-targeted PET/CT Imaging in Hematological Malignancies NCT05255926 | Zhongnan Hospital | N/A |
| Active Not Recruiting | SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignanci NCT04684108 | Hangzhou Sumgen Biotech Co., Ltd. | Phase 1 |
| Completed | Use of nMoABs for the Treatment of COVID-19 in Patients With HM. NCT04932967 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Completed | Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies NCT05391022 | Constellation Pharmaceuticals | Phase 1 |
| Completed | Systematic Symptom Identification With Disease Specific PROM to Assess Symptoms of Chronic GVHD in Outpatient NCT04884204 | Rigshospitalet, Denmark | N/A |
| Unknown | A Mixed Method to Study Adherence to Oral Anticancer Medications in a Multilingual and Multicultural Setting NCT04613765 | Jules Bordet Institute | — |
| Terminated | Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid NCT04305249 | Antengene Therapeutics Limited | Phase 1 |
| Unknown | Clinical Study of CAR-T Technology for the Treatment of Relapsed Refractory Malignant Haematological Tumours NCT06238336 | Shanxi Bethune Hospital | Phase 2 / Phase 3 |
| Terminated | Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19 NCT04347226 | Columbia University | Phase 2 |
| Recruiting | Membrane Target Detection for Leukemia Treatment NCT04841447 | University of Missouri-Columbia | — |
| Unknown | CAR-T Cellular Therapy for B Cell Malignancies Involved in CNS NCT04287309 | Zhejiang University | — |
| Withdrawn | Dual PD-1 and JAK2 Inhibition in Hematological Malignancies NCT04016116 | NYU Langone Health | Phase 2 |
| Terminated | Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy NCT04093622 | Fate Therapeutics | — |
| Unknown | Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells NCT04082910 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Completed | Comprehensive Study of Social Representation of Platelet Transfusion in Patients Followed for Advanced Hematol NCT03806712 | Centre Hospitalier Universitaire de Besancon | — |
| Completed | VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies NCT03885947 | Alla Keyzner | Phase 1 |
| Unknown | MS Detection of Somatic Mutations in Hematological Malignancies NCT03771079 | University Hospital, Strasbourg, France | — |
| Completed | Feasibility and Efficacy of Modified Donor Lymphocytes Infusion (CD45RA Negative Selected) After Haploidentica NCT04687982 | Istituto Clinico Humanitas | N/A |
| Terminated | Body Scan Activity on Bone Marrow Transplant Patients and Their Caregivers NCT03611764 | Washington University School of Medicine | Phase 1 |
| Completed | Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Base NCT03159702 | Medical College of Wisconsin | Phase 2 |
| Completed | A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients NCT03241550 | Astellas Pharma Global Development, Inc. | Phase 1 |
| Unknown | Impact of a Monitoring Device for Patients With Cancer Treated Using Oral Therapeutics NCT02828462 | Gustave Roussy, Cancer Campus, Grand Paris | — |
| Unknown | Effects of Exercise on Allogeneic Stem Cell Transplant NCT02900768 | Raewyn Broady | N/A |
| Recruiting | HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortez NCT03850366 | Henry Ford Health System | Phase 2 |
| Recruiting | Bergonie Institut Profiling : Fighting Cancer by Matching Molecular Alterations and Drugs in Early Phase Trial NCT02534649 | Institut Bergonié | N/A |
| Completed | Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell Transplanta NCT02598752 | Memorial Sloan Kettering Cancer Center | — |
| Terminated | Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL NCT02361346 | Molecular Templates, Inc. | Phase 1 / Phase 2 |
| Completed | Prognosis of Hematological Cancer Patient Underwent Mechanical Ventillation NCT02562105 | Mansoura University | — |
| Completed | Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology P NCT02149329 | Amsterdam UMC, location VUmc | Phase 4 |
| Completed | Early Antibiotic Discontinuation in FUO NCT02906254 | University Hospital, Brest | — |
| Completed | The Effect of Special Diets in Hematological Cancer Patients NCT02880709 | Jens Rikardt Andersen | Phase 4 |
| Completed | Phase I of Infusion of Selected Donor NK Cells After Allogeneic Stem Cell Transplantation NCT01853358 | Institut Paoli-Calmettes | Phase 1 |
| Unknown | Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation NCT01757145 | Rabin Medical Center | Phase 2 |
| Completed | Effect of Body Mass on Filgrastim Pharmacokinetics NCT01719432 | Aaron Cumpston, PharmD, BCOP | — |
| Completed | Effect of Body Mass on Acyclovir Pharmacokinetics NCT01714180 | West Virginia University | — |
| Completed | Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis NCT01860170 | Corewell Health West | Phase 1 / Phase 2 |
| Completed | A New Dosing Regimen for Posaconazole Prophylaxis in Children Based on Body Surface Area NCT02372357 | Universitaire Ziekenhuizen KU Leuven | Phase 4 |
| Completed | Prospective Clinical Evaluation of Beta-D-Glucan Assay in Blood and BAL NCT01576653 | Robert Krause, MD | N/A |
| Completed | A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy NCT00558675 | Mirror Biologics, Inc. | Phase 1 / Phase 2 |
| Completed | A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies NCT01317927 | Spectrum Pharmaceuticals, Inc | Phase 1 |
| Completed | Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ NCT01084252 | Sanofi | Phase 1 / Phase 2 |
| Completed | Suicide Gene Therapy for Donor Lymphocytes Infusion After Allogeneic Hematopoietic Stem Cell Transplantation NCT01086735 | Assistance Publique - Hôpitaux de Paris | Phase 1 / Phase 2 |
| Completed | Umbilical Cord Blood Transplantation As Treatment Of Adult Patients With Hematologic Disorders NCT00897260 | University of British Columbia | N/A |
| Completed | Pharmacologic Optimization of Voriconazole NCT00893555 | Jan-Willem C Alffenaar | Phase 3 |
| Completed | A Study Comparing Non Myeloablative (Flu-TBI) and Reduced Intensity (FLU-BU-ATG) Conditioning in Allogenic Tra NCT00894049 | Institut Paoli-Calmettes | Phase 2 |
| Withdrawn | Treatment of Patients With Donor Lymphocytes Sensitized by Antigens Expressed by the Host NCT00149032 | Hadassah Medical Organization | Phase 2 |
| Completed | Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patien NCT00195533 | Wyeth is now a wholly owned subsidiary of Pfizer | — |